（来源：财闻） "八连板"胜通能源称，如未来公司股票价格进一步上涨，公司可能向深圳证券交易所申请停牌核查。 项目投资 九丰能源（605090.SH）：公司特种气体业务的战略定位为航空航天特气，并锚定商业航天特燃特气需 求领域。除海南商业航天发射场特燃特气配套项目外，公司积极拓展山东海阳东方航天港、甘肃酒泉卫 星发射中心等其他商业航天发射基地的特燃特气合作项目，并全部进入实施阶段。 截至目前，公司多次与上海航天设备制造总厂有限公司（隶属中国航天科技集团有限公司第八研究院） 签署相关协议；公司多次与中国航天科技集团商业火箭有限公司（隶属中国航天科技集团有限公司）签 署相关协议；公司与中国长征火箭有限公司（隶属中国航天科技集团有限公司第一研究院）签署相关协 议，与北京天兵科技有限公司签署相关协议；公司已中标上海空间推进研究所（隶属中国航天科技集团 有限公司第六研究院）三年期氦气、氮气等产品综合保障服务项目。 重大合同 宁波华翔（002048.SZ）：公司下属子公司宁波华翔启源科技有限公司与国内某头部机器人关节厂商签 订了《机器人关节委托生产合同》，将在未来两年内为其生产制造部分机器人关节产品。该合作将有利 于华翔启 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於公司控股股東、實際控制人之一因非本公司事項收到<行政處罰決定書>的公 告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年12月23日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 一 ...

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, has been penalized approximately 19.34 million yuan for insider trading and related activities, which includes the confiscation of illegal gains and fines imposed by the China Securities Regulatory Commission [1][2]. Group 1: Penalty Details - Jiang Wei was fined 1.463 million yuan and had illegal gains of 471 million yuan confiscated by the China Securities Regulatory Commission [1][2]. - The penalty is directed at Jiang Wei personally and is stated to have no significant impact on the company's daily operations or financial status [4]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei holds 66.528 million shares, representing 28.6% of Haohai Biological Technology's total shares [4]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [5]. Group 3: Business Developments - Haohai Biological Technology plans to invest 38.3515 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [6]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [6]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.7415 million yuan for 2024, with a loss of 11.9327 million yuan in the first nine months of 2025 [7][8]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological Technology if Ruiji's performance declines [8].

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and related activities, which the company claims will not significantly impact its operations or finances [2][4][6]. Group 1: Penalty Details - Jiang Wei was fined 1,463 million yuan and had 471 million yuan of illegal gains confiscated by the China Securities Regulatory Commission (CSRC) [4][6]. - The penalty is directed at Jiang Wei personally and is stated to be unrelated to the company's operations [6][7]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological, holding 66.528 million shares, which accounts for 28.6% of the total shares [7][8]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [8]. Group 3: Business Developments - Haohai Biological plans to invest 38.35 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [11][12]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [11]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.74 million yuan for 2024, with a loss of 11.93 million yuan in the first three quarters of the current year [12][13]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological if Ruiji's performance declines [13]. Group 5: Market Position - As of December 23, Haohai Biological's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [14].

Macro Dynamics - Beijing has issued the first batch of L3-level highway autonomous vehicle special license plates, marking a significant milestone in the country's autonomous driving era. The "conditionally automated driving" feature is currently limited to specific highway sections in Beijing [2] - The State Administration for Market Regulation will soon implement strict regulations on food safety responsibilities for live-streaming e-commerce operators, establishing clear guidelines and penalties for non-compliance [3][4] - By 2026, China plans to build over 10,000 charging guns in highway service areas, with at least 25% being high-power chargers, to enhance electric vehicle charging infrastructure [5] - The Chinese Foreign Ministry has expressed strong opposition to the U.S. adding DJI drones to a restricted list, criticizing the discriminatory practices against Chinese companies [6] - A radioactive water leak occurred at a decommissioned nuclear reactor in Japan, potentially exposing several individuals to radiation [7] Financial Institutions - Hangzhou Bank plans to issue financial bonds not exceeding 40 billion RMB, with a maturity of up to 10 years [8] - The CEO of Bank of America highlighted the increasing impact of AI investments on the U.S. economy, suggesting that AI will play a significant role in future economic contributions [9] Market Data - On December 23, the market experienced a pullback after an initial rise, with the Shanghai Composite Index up by 0.07% and the Shenzhen Component Index up by 0.27%. New stocks listed on the same day saw significant gains [10] - As of December 22, the total margin balance in the two markets increased by 12.534 billion RMB, indicating a growing interest in leveraged trading [11] - The Hong Kong Hang Seng Index closed down by 0.11%, with notable movements in gold stocks and declines in certain tech stocks [12] Company Dynamics - Oriental Yuhong reported that its U.S. subsidiary fell victim to a telecom fraud involving approximately 12.118 million RMB, but the incident is not expected to significantly impact the company's operations [13] - Zhongxin Tourism has established three subsidiaries in Hainan and is actively expanding its tourism-related business in the region [14] - Haohai Biological Technology's controlling shareholder was fined 14.6292 million RMB for insider trading, but this will not affect the company's daily operations [15][16] - The co-founder of the game "Call of Duty," Vince Zampella, tragically passed away in a car accident [17] - Jiangbolong indicated that rising prices of storage wafers would positively impact the company's gross margin, supported by long-term supply agreements with major wafer manufacturers [18]

智通财经APP讯，昊海生科(688366.SH)发布公告，公司控股股东、实际控制人之一蒋伟因内幕交易、 建议他人买卖证券行为，收到中国证监会出具的《行政处罚决定书》，被没收违法所得471万元，并处 以1462.92万元罚款。该处罚决定书所涉主体为蒋伟个人，涉及的事项与公司无关，不会对公司日常经 营、业务及财务造成重大影响。 ...

昊海生科2025年第三季度报告显示，蒋伟系公司第一大股东，直接持股数量为6652.8万股，持股比例为 28.6%；公司第二大股东为游捷，直接持股数量为4032万股，持股比例为17.34%。蒋伟和游捷为夫妻关 系，是公司控股股东、实际控制人。 昊海生科彼时表示，本次事项系对蒋伟个人的调查，其不参与公司日常经营管理，该事项不会对公司日 常经营活动产生重大影响。立案调查期间，蒋伟将积极配合中国证监会开展调查工作。 之后，昊海生科又于2025 年9 月17日公告，蒋伟于近日收到中国证监会出具的《行政处罚事先告知 书》。 昊海生科是一家从事医疗器械和药品研发、生产和销售业务的科技创新型企业，致力于通过技术创新及 转化、国内外资源整合及规模化生产，为市场提供创新医疗产品，逐步实现相关医药产品的进口替代， 成为生物医用材料领域的领军企业。 昊海生科(688366)12月23日晚公告，近日，公司收到控股股东、实际控制人之一蒋伟告知，获悉其收到 了中国证监会出具的《行政处罚决定书》（[2025]151 号）。行政处罚决定书的主要内容为：因蒋伟内 幕交易、建议他人买卖证券行为，中国证监会决定没收其违法所得470.97万 元，并对 ...

北京商报讯（记者 丁宁）12月23日晚间，昊海生科（688366）发布公告称，近日， 公司收到控股股 东、实际控制人之一蒋伟告知，获悉其收到了中国证监会出具的《行政处罚决定书》 。行政处罚决定 书的主要内容为，因蒋伟内幕交易、建议他人买卖证券行为，中国证监会决定没收其违法所得470.97万 元，并对其处以1462.92万元罚款，合计约1933.9万元。 昊海生科表示，该 《行政处罚决定书》 所涉主体为蒋伟个人，涉及的事项与公司无关。蒋伟不参与公 司日常经营管理，该事项不会对公司日常经营、业务及财务造成重大影响。截至公告披露日，公司各项 生产经营活动正常有序开展。 ...

北京商报讯（记者 王寅浩 宋雨盈）12月23日，吴海生科发布公告称，公司控股股东、实际控制人之一 蒋伟因内幕交易、建议他人买卖证券行为，收到中国证券监督管理委员会出具的《行政处罚决定书》， 没收其违法所得470.97万元并处以1462.92万元罚款。根据公告，该《行政处罚决定书》所涉主体为蒋伟 个人，涉及的事项与公司无关。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月23日 第 1 頁 共 11 頁 v 1.3.0 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | 10,000 | % | HKD | 27.68 | | | 變動日期 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | 18,400 | % | HKD | 28 | | | 變動日期 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | 23,500 | % | HKD | 27. ...